It’s well known that private equity has drastically increased its presence in the healthcare industry, acquiring hospitals, physician practices and other providers. These acquisitions have received scrutiny following the bankruptcies

Oncology remains one of the most challenging areas for payers since it is literally in the eye of a perfect storm of expensive medications, high-cost specialized therapies, changing reimbursement rules

One of the standard treatments for idiopathic pulmonary fibrosis is an old drug that offers limited efficacy and a range of side effects. Celea Therapeutics aims to offer advantages over

Many blood cancers can be treated with a potentially curative stem cell transplant, but this procedure introduces a serious complication risk that can become deadly. A new type of cell

If you have interacted in the past few years with a medical chatbot, you probably walked away feeling like it was helpful for simple tasks and frustrating for anything even

The recent attention surrounding hantavirus has understandably unsettled people. A virus associated with rodents, severe respiratory illness, and mortality rates that can exceed 35% is going to generate concern whenever

The Office of Personnel Management recently made headlines by requesting health claims data for workers covered under the Federal Employees Health Benefits (FEHB) program. The government needs this itemized data to ensure

UnitedHealthcare Group opened its doors to a group of journalists and influencers at its headquarters last month and MedCity News Editor-in-Chief Arundhati Parmar was among them. On the latest episode

Roche is a relative latecomer in the chase to block a protein called KRAS G12C to treat lung cancer, but the pharmaceutical company has been testing its contender head-to-head against

This week, the FDA granted breakthrough device designation to Aurenar‘s V-Link system, a non-invasive nerve stimulation device designed to treat cerebral vasospasm. Vasospasm is one of the most dangerous complications